MedTrace Logo

Treatment of Ocular Surface Inflammations

NCT07732855 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-08-03

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if topical Cyclosporine 1% works to treat severe allergic ocular surface inflammation in pediatric population. The study will evaluate the efficacy and safety of topical Cyclosporine 1%.

The main questions it aims to answer are:

Does topical Cyclosporine 1% lower the number of times participants need to use a rescue steroid? What medical problems do participants have when taking topical Cyclosporine 1%?

Participants will:

Take topical Cyclosporine 1% every day for months. Visit the clinic once every 2-6 weeks for checkups and tests. Keep a diary of their symptoms and the number of times they use a rescue medication. spelling errors/typos and update as appropriate.

Conditions

  • Ocular Surface Allergy
  • Conjunctivitis, Allergic
  • Blepharoconjunctivitis

Interventions

DRUG

Topical Cyclosporine 1%

Dosage may differ from severe dry eye indication

Sponsors & Collaborators

  • Semmelweis University

    lead OTHER

Principal Investigators

  • Amarilla Barcsay-Veres, MD · Semmelweis University

Eligibility

Min Age
4 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-10
Primary Completion
2026-12-31
Completion
2028-12-31

Countries

  • Hungary

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07732855 on ClinicalTrials.gov